Highlights

  • Bausch Health shares rose more than 11% on December 01, 2025.
  • Solta Medical completed the acquisition of Wuhan Shibo Zhenmei Technology.
  • The deal brings Solta’s product distribution in China directly under its control.

Bausch Health Companies (NYSE:BHC) closed higher on December 01, 2025, rising at a double-digit rate on a day when the broader U.S. market fell. The S&P 500 and Nasdaq Composite ended lower, but Bausch Health moved in the opposite direction. The stock climbed more than 11% after the company announced a strategic move involving its aesthetics business.

The reaction followed early-morning news from the company related to its Solta Medical unit.

Solta Medical Brings Chinese Distributor In-House

Before the market opened, Bausch Health announced that Solta Medical had completed the acquisition of Wuhan Shibo Zhenmei Technology, a long-time distributor of Solta products in China. The deal shifts the distribution function in-house, giving Solta direct oversight of product reach in one of the largest aesthetics markets globally.

The company said, “This acquisition provides Solta Medical with an enhanced ability to address increasing market demand for aesthetics treatments through localized solutions and proven technologies.”

Solta Medical’s portfolio includes Thermage FLX, a non-invasive skin-tightening solution that is widely used in China. The acquisition is expected to streamline access to this offering by consolidating distribution capabilities.

Market Response and Lack of Financial Detail

Bausch Health did not disclose transaction terms or financial details related to the acquisition. Market participants reacted to the operational implications rather than specific cost metrics. Bringing distribution in-house gives Solta Medical broader control over a key region where demand for aesthetics treatments continues to expand.

Despite the lack of disclosed figures, the move was viewed as significant for Solta’s Asia-focused operations. The acquisition adds scale and direct presence in China’s competitive aesthetics segment.

The stock’s double-digit rise on December 01, 2025, highlights the impact of strategic updates during a session when broader equity benchmarks were under pressure.